Archford Capital Strategies LLC Sells 8,320 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Archford Capital Strategies LLC reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 69.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,648 shares of the medical research company's stock after selling 8,320 shares during the period. Archford Capital Strategies LLC's holdings in IQVIA were worth $643,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. American National Bank & Trust acquired a new position in shares of IQVIA in the 1st quarter valued at $26,000. ST Germain D J Co. Inc. lifted its stake in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the period. GKV Capital Management Co. Inc. acquired a new position in shares of IQVIA during the 4th quarter worth about $39,000. Lee Danner & Bass Inc. acquired a new position in shares of IQVIA during the 4th quarter worth about $44,000. Finally, Zions Bancorporation N.A. raised its position in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares during the period. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on IQV shares. Truist Financial lowered their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. JPMorgan Chase & Co. dropped their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Mizuho decreased their target price on IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. Redburn Partners set a $188.00 price target on IQVIA in a research report on Friday, May 23rd. Finally, Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Stock Performance

Shares of IQV traded down $0.30 during midday trading on Friday, reaching $157.86. The stock had a trading volume of 237,949 shares, compared to its average volume of 1,648,680. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The firm has a 50 day simple moving average of $148.98 and a 200-day simple moving average of $174.85. The firm has a market cap of $27.31 billion, a PE ratio of 21.49, a P/E/G ratio of 1.74 and a beta of 1.28. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the previous year, the business earned $2.54 earnings per share. The business's revenue was up 2.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.